Skip to main content

Nutex Health Inc 8-K, filed May 15, 2020

Nutex Health Inc. (NUTX)

8-K 2020-05-15 For: 2020-05-15
View Original
Added on April 10, 2026

About this 8-K

Nutex Health Inc filed this 8-K on May 15, 2020.

Items reported

  • Item 8.01: Other events

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

Pursuantto Section 13 OR 15(d) of

TheSecurities Exchange Act of 1934

Dateof Report (Date of earliest event reported) May 15, 2020

ClinigenceHoldings, Inc.

(Exactname of registrant as specified in its charter)

Delaware 000-53862 11-3363609
(State or other jurisdiction<br><br> <br>of incorporation) (Commission File Number) (IRS Employer<br><br> <br>Identification No.)
55 Ivan Allen Jr. Blvd. NW, #875<br><br> <br>Atlanta, Georgia 30308
--- ---
(Address of principal executive offices) (Zip Code)

Registrant’stelephone number, including area code: (678) 607-6393

(Formername or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securitiesregistered pursuant to Section 12(b) of the Act:


Title of each class Trading<br><br> <br>Symbol(s) Name of each exchange<br><br> <br>on which registered
Common Stock, $0.001 par value CLNH OTCMKTS

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


| 1 |

| --- |


Item8.01 Other Events.

Due to the outbreak of coronavirus disease in 2019 (COVID-19), Clinigence Holdings, Inc, (the “Company”) is filing this current report on Form 8-K to avail itself of an extension to file its quarterly report on Form 10-Q for the period ended March 31, 2020, originally due on May 15, 2020 (the “Quarterly Report”), because additional time is required by Registrant’s management and auditors to prepare certain financial information to be included in such report.

The Company evaluated its ongoing effort to prepare and file its Quarterly Report and is unable to do so because of the impact of COVID-19, which, among other things, due to travel limitations and the requirements of “social distancing,” has adversely impacted and continues to adversely impact the ability of the individuals performing the required evaluation tasks to complete the filing on a timely basis.

Certain Company officers and management as well as professional staff and consultants are unable to conduct work required to prepare our financial report for the period ended March 31, 2020. As a result, the Company expects to be unable to compile and review certain information required in order to permit the Company to file a timely and accurate quarterly report on Form 10-Q for the period ended March 31, 2020 by the prescribed date without unreasonable effort or expense due to circumstances related to COVID-19.

Accordingly, as and to the extent the Company is unable to file the Quarterly Report on the due date, we are relying upon the order (the “Order”) issued by the Securities and Exchange Commission (the “SEC”) on March 4, 2020 pursuant to Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), extending the time (the “Extended Extension Period”) in which certain reports required to be filed pursuant to the Exchange Act are filed, and we are furnishing this Form 8-K as required pursuant to such order.

The Company is supplementing the risk factors previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2019 and its current Reports on Form 8-K, with the following risk factors:

Theoccurrence of an uncontrollable event such as the COVID-19 pandemic may negatively affect our operations.

A pandemic typically results in social distancing, travel bans and quarantine, and this may limit access to our facilities, customers, management, support staff and professional advisors. These factors, in turn, may not only impact our operations, financial condition and demand for our goods and services but our overall ability to react timely to mitigate the impact of this event. Also, it may hamper our efforts to comply with our filing obligations with the Securities and Exchange Commission.

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Clinigence Holdings, Inc.
Date: May 15, 2020 /s/ Elisa Luqman
Elisa Luqman
Chief Financial Officer
| 3 |

| --- |